[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636017":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas & Co",null,"metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas \\& Co",[13],"Diagnostic Test: Archived FFPE tissue biopsy and\u002For newly acquired liquid biopsy for molecular profiling.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Archived FFPE tissue biopsy and\u002For newly acquired liquid biopsy for molecular profiling.","The exposure\u002Fintervention under investigation is the use of archived FFPE tissue biopsy and\u002For newly acquired liquid biopsy for molecular profiling.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Research Site","São Paulo","Brazil","BR",{"type":33,"coordinates":34},"Point",[35,36],-46.63611,-23.5475,{"lat":36,"lon":35},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100636017","promet-br---molecular-profiling-of-metastatic-prostate-cancer-a-brazilian-cohort-100636017",false,"NCT07560215","PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort","A Retrospective and Prospective Study Aiming to Characterize Molecular Alterations and Clinical Outcomes of Metastatic Prostate Cancer in a Real-world Cohort of Patients Eligible to Palliative Systemic Therapy at Oncoclínicas & Co Group","PROMET-BR","Inclusion Criteria:\n\n* Adult patients age \\>= 18 years; clinical diagnosis of metastatic prostate cancer (irrespective of hormone-sensitivity or castration-resistance status); eligible to palliative therapy for metastatic prostate cancer at Oncoclínicas \\& Co in 2023 onwards; sufficient FFPE tissue available for molecular profiling. For the subset of patients prospectively selected to liquid biopsy cohort, clinical or radiological evidence of disease progression at the sample collection, and with at least 14 days of treatment interval from last dose of systemic anticancer therapy or radiotherapy to liquid biopsy.\n\nExclusion Criteria:\n\n* No tissue FFPE tissue available for molecular profiling (except in prospective liquid biopsy cohort); less than 3 months follow-up from start of palliative therapy for metastatic prostate cancer at Oncoclínicas \\& Co.","MALE","18 Years","99 Years",{"count":52,"type":53},100,"ESTIMATED","OBSERVATIONAL","PROMET-BR is an observational, retrospective and prospective real-world study in Brazil designed to characterize clinically relevant molecular alterations in metastatic prostate cancer and explore their association with patient outcomes in routine practice. The study will be conducted within Oncoclínicas \\& Co and will integrate centralized biomarker testing performed at OC Precision Medicine laboratories with retrospectively assembled clinical data from electronic health records (EHRs) from participating sites. Treatments are not assigned by the protocol; patients receive standard-of-care palliative systemic therapy at the discretion of their treating physicians.",[57],"Metastatic Prostate Cancer","NOT_YET_RECRUITING","2026-04-24",{"date":61,"type":62},"2026-05-01","ACTUAL",{"date":64,"type":53},"2026-04-30",{"date":66,"type":53},"2027-03-31",{"name":5,"class":6},1]